Compare General Dynamics Corporation (GD) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Heron Therapeutics Inc — how do they compare? General Dynamics Corporation trades at $328.29 (market cap $89.26B), while Heron Therapeutics Inc trades at $0.36 (market cap $68.01M). The key difference: General Dynamics Corporation is far larger — about 1312.5× Heron Therapeutics Inc's market cap, and General Dynamics Corporation pays a 1.93% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Heron Therapeutics Inc for 35 Days on average.
| GD | HRTX | |
|---|---|---|
Market Cap | $89.26B | $68.01M |
Volume | 1,496,273 | 1,891,941 |
Sector | Industrials | Health |
52-Week High | $395.97 | $1.49 |
52-Week Low | $312.53 | $0.27 |
Typical Hold Time | 85 Days | 35 Days |
Enterprise Value | $94.40B | $174.75M |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $326.63, down 1.42% amid bearish technical signals, though fundamentals remain solid with consistent earnings beats and strong defense contract visibility. The stock shows oversold RSI readings while maintaining healthy profitability metrics including 8.18% net margin and 17.8% ROE. Recent Pentagon spending focus and dividend stability support the investment case despite near-term price pressure.
GD presents a compelling value opportunity with 57% analyst buy ratings and $420.57 consensus target representing 29% upside. Defense budget tailwinds and submarine/vehicle demand provide growth catalysts, though technical weakness and defense sector volatility pose near-term risks. The company's consistent cash flow generation and dividend payments offer stability for long-term investors.
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
